Race of b/tsDMARDs in RA, the “JAK-pot” study. JAKi and TNFi with more rapid early improvement in CDIA, HAQ, and pain compared to ABA or IL-6 inhibitors…..although effects blunted after adjusting for patient and RA characteristics #ACR24 @RheumNow ABST#0501 https://t.co/8M4wX3LAbW

• https://x.com/JihaRheum/status/1857895166117384500/photo/1

Abstract #0805 Data from OTIS Registry shows Certolizumab pegol (Cimzia) exposure during pregnancy was not associated with increased risk of major birth defects, structural defects, or adverse pregnancy outcomes. #ACR24 @RheumNow

Is it safe to administer rotavirus vaccine to infants exposed in utero to TNFi? Abstract#0806 shows no significant ↑ in the risk of diarrhea-related healthcare events among TNFi-exposed infants who received the vaccine compared to those who did not @RheumNow #ACR24 https://t.co/HpTCgywE4H

• https://x.com/AkhilSoodMD/status/1857857417427709966/photo/1

❔Can rheum drugs have beneficial effects on cognition? 💊Possible benefits with MTX and TNFis but certainly an active area of research and more studies needed #ACR24 @RheumNow https://t.co/lCnIRLwNjK

• https://x.com/DrMiniDey/status/1857852286778634671/photo/1

Switching vs cycling - which is better? In PsA & axSpA, a real-world analysis shows that switching to IL-17Ai after TNFi discontinuation may lead to similar or better outcomes compared to cycling to another TNFi. Data from the CorEvitas PsA/SpA Registry. Abstr#0585.… https://t.co/AJP4NBjmzr

• https://x.com/i/web/status/1857827218912849961

Courvoisier et al. JAK-pot study analysis. Which therapies work quicker in RA? JAKi (as expected) and TNFi (what!?) faster than IL6 and abatacept. @RheumNow #ACR24 Abstr#0501 https://t.co/7DPPwHlqpP https://t.co/3mOJ62hZhp

• How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act i…
• https://x.com/RichardPAConway/status/1857823192204677592/photo/1

Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. In 23.3% ILD progressed on abatacept. Is that good or bad? We need comparative studies! @RheumNow #ACR24 Abstr#0475 https://t.co/nUEDdjGguA https://t.co/sXEF72MafK

• Rheumatoid Arthritis - Progressive Interstitial Lung Disease with Abatacept: Da…
• https://x.com/RichardPAConway/status/1857821934110572580/photo/1

PRO-SPIRIT trial data on 1192 PsA pts showed IL-17Ai seemed better than IL-12/23i and IL-23i improving cDAPSA at 3m and as effective as TNFi and JAKi. No much differences seen at 12m. Abst#0076 #ACR24 @RheumNow https://t.co/dScwsmkDOe

• https://x.com/AdelaCastro222/status/1857819668875968932/photo/1

With many treatments for #PsA and #PsO, what are the prescribing trends? Abstract 0604: TNF inhibitors remain the most common (~60%), but over the past 10 years, IL-17i use rose from 0.2% to 19%, and IL-23i from 0.1% to 39.7%! #ACR24 @RheumNow https://t.co/4TnCAkHfuY

• https://x.com/AkhilSoodMD/status/1857820424018755876/photo/1

Cool data from the JAK-POT study Have heard JAKs faster than TNF; perhaps not the case! If anything, TNFs outperformed the others in this study Trying not to over-read this, but supports my re-emerging preference for TNF #ACR24 @rheumnow Abstr#0501 https://t.co/NDyPwju3ds

• https://x.com/EBRheum/status/1857813881176854579/photo/1
• https://x.com/EBRheum/status/1857813881176854579/photo/1

🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure: -Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie #ACR24 @RheumNow https://t.co/Jc0cdmrVhI

• https://x.com/AdelaCastro222/status/1857810860795638038/photo/1

#0501 💥 JAKi & TNFi show faster short-term RA improvement (3months) compared to IL-6i & ABA ➡️n=9590(3049 JAKi, 4606 TNFi, 1284 IL-6, 651 ABA), 14 registers 🕒 JAKi, TNFi improved CDAI, pain, function in 1st two months then stabilised 💡Long-term data needed #ACR24 @RheumNow https://t.co/4yzeAAkGjq

• https://x.com/CaoilfhionnMD/status/1857806079457136834/photo/1

TNFi cycling vs. switching to IL-17Ai? Dr @AlexisOgdie et al from CorEvitas registry: PsA & axSpA cohort - switchers (TNFi to IL17i) had greater improvements in cDAPSA & BASDAI vs. cyclers (2nd TNF) Not stat significant but offers alternative Tx options @RheumNow #ACR24 abs585 https://t.co/8m347BRM75

• https://x.com/RHEUMarampa/status/1857798800645218461/photo/1